We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
Cap. Flow
-$105M
Cap. Flow %
-4.06%
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$42.8M
2
ABBV icon
AbbVie
ABBV
+$22.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.8M
4
CELG
Celgene Corp
CELG
+$14.3M
5
NVO
Novo Nordisk
NVO
+$10.1M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$25.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$24.3M
3
AGN
Allergan plc
AGN
+$23.5M
4
GILD icon
Gilead Sciences
GILD
+$21.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.75%
2 Real Estate 2.87%
3 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
126
DELISTED
Cymabay Therapeutics
CBAY
$1.93M 0.07%
209,962
– –
AFMD
127
DELISTED
Affimed
AFMD
$1.83M 0.07%
140,532
– –
ACHN
128
DELISTED
Achillion Pharmaceuticals
ACHN
$1.77M 0.07%
616,000
– –
SNDX icon
129
Syndax Pharmaceuticals
SNDX
$1.73B
$1.75M 0.07%
200,000
– –
PTGX icon
130
Protagonist Therapeutics
PTGX
$8.92B
$1.72M 0.07%
82,822
+75,000
+959% +$1.33M
EVH icon
131
Evolent Health
EVH
$358M
$1.51M 0.06%
122,500
– –
GKOS icon
132
Glaukos
GKOS
$9.9B
$1.41M 0.05%
55,079
-8,628
-14% -$257K
DHR icon
133
Danaher
DHR
$138B
$1.41M 0.05%
+17,149
New +$1.39M
SNN icon
134
Smith & Nephew
SNN
$13.6B
$1.41M 0.05%
+40,183
New +$1.46M
ISRG icon
135
Intuitive Surgical
ISRG
$126B
$1.41M 0.05%
+11,550
New +$1.45M
MNK
136
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$1.4M 0.05%
61,900
– –
HR icon
137
Healthcare Realty
HR
$7.46B
$1.38M 0.05%
46,000
– –
WELL icon
138
Welltower
WELL
$170B
$1.36M 0.05%
21,400
– –
DOC icon
139
Healthpeak Properties
DOC
$15.2B
$1.19M 0.05%
45,500
– –
RVNC
140
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.15M 0.04%
+32,225
New +$925K
ORKA
141
Oruka Therapeutics
ORKA
$5.9B
$1.11M 0.04%
3,756
– –
QTNT
142
DELISTED
Quotient Limited Ordinary Shares
QTNT
$1.04M 0.04%
5,238
+2,266
+76% +$436K
XENE icon
143
Xenon Pharmaceuticals
XENE
$6.2B
$989K 0.04%
350,000
– –
CYH icon
144
Community Health Systems
CYH
$391M
$869K 0.03%
203,935
– –
CHRS icon
145
Coherus Oncology
CHRS
$227M
$792K 0.03%
90,000
– –
NVAX icon
146
Novavax
NVAX
$1.22B
$708K 0.03%
28,550
– –
XRN
147
Chiron Real Estate Inc
XRN
$516M
$602K 0.02%
14,680
– –
NSTG
148
DELISTED
NanoString Technologies, Inc.
NSTG
$555K 0.02%
74,250
-39,250
-35% -$372K
BLCM
149
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$505K 0.02%
6,000
– –
CYTO
150
DELISTED
Altamira Therapeutics Ltd
CYTO
$457K 0.02%
10
– –
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.

  • Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
  • Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
  • Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
  • Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
  • Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
  • Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.